<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>FDA tells GLP-1 makers to warn of potential vision loss side effect — Live Feed</title><link>https://www.live-feeds.com/feed/fda-tells-glp-1-makers-to-warn-of-potential-vision-loss-side-effect</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/fda-tells-glp-1-makers-to-warn-of-potential-vision-loss-side-effect/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA orders vision-loss warning on GLP-1 weight-loss drugs</title><link>https://www.live-feeds.com/feed/fda-tells-glp-1-makers-to-warn-of-potential-vision-loss-side-effect</link><guid isPermaLink="false">https://www.live-feeds.com/feed/fda-tells-glp-1-makers-to-warn-of-potential-vision-loss-side-effect#u203288</guid><pubDate>Mon, 16 Nov 2026 02:27:59 +0000</pubDate><description>The U.S. Food and Drug Administration has directed manufacturers of popular GLP-1 drugs including Ozempic, Wegovy, Zepbound and Mounjaro to add warnings about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) that can cause sudden, permanent vision loss. The agency said it identified a potential safety signal after reviewing adverse-event reports and published studies. Drugmakers must update prescribing information and patient medication guides to reflect the risk. The drugs remain on the market and the FDA has not recommended patients stop taking them.Why it</description></item>
</channel></rss>